PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Euronext Paris 17:30:00 15/07/2024 BST | ||
| 3.205 EUR | +0.63% |
|
| Current month | +15.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 15/07/24 | 3.205 | +0.63% |
| 12/07/24 | 3.185 | -5.91% |
| 11/07/24 | 3.385 | +8.32% |
| 10/07/24 | 3.125 | -3.99% |
| 09/07/24 | 3.255 | +9.05% |
Real-time Euronext Paris
Last update July 15, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| CG64V | |
| ISIN | DE000VD8TUY0 |
| Date issued | 28/06/2024 |
| Strike | 1,206 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.82 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.575 € |
|---|---|
| Lowest since issue | 2.635 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.72%
- Stock Market
- Certificates
- CG64V Certificat
